Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
42.67
+0.53 (1.26%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 778 employees as of December 31, 2025. The number of employees increased by 104 or 15.43% compared to the previous year. That makes Supernus Pharmaceuticals the 16,759th largest employer in the world and 2,364th in the United States.
Employees
778
Change (1Y)
104
Growth (1Y)
15.43%
Revenue / Employee
$1,067,401
Profits / Employee
-$141,242
Market Cap
2.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 778 | 104 | 15.43% |
| Dec 31, 2024 | 674 | 22 | 3.37% |
| Dec 31, 2023 | 652 | 40 | 6.54% |
| Dec 31, 2022 | 612 | 37 | 6.43% |
| Jun 30, 2022 | 603 | - | - |
| Dec 31, 2021 | 575 | 12 | 2.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| HUTCHMED (China) | 1,790 |
| Alvotech | 1,279 |
| Prestige Consumer Healthcare | 890 |
| BioCryst Pharmaceuticals | 435 |
| Xeris Biopharma Holdings | 435 |
SUPN News
- 3 days ago - Supernus Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - Supernus Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - Supernus Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Supernus Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - Supernus Pharmaceuticals to Participate in September Investor Conferences - GlobeNewsWire
- 5 weeks ago - Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Supernus Pharmaceuticals Earnings release: Q2 2026 - Filings